News

A new liquid biopsy platform has been developed that uses RNA "dark matter" to diagnose cancer types including pancreatic, lung and esophageal, in the early stages.

Scientists have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to it.

A new study has shown why tumors that have spread to the brain respond to immunotherapy while cancers that originate in the brain, like glioblastoma, do not.

Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless of cause in patients with ulcerative colitis.

Combination drug and immunotherapy treatment can extend survival in patients with gliomas, a highly aggressive form of brain cancer, suggests a new Phase 1, first-in-human trial.

Doxorubicin can induce oxidative stress in a cell’s endoplasmic reticulum (ER) and severe ER impairment in cardiomyocytes can lead to cardiac dysfunction. Researchers have now discovered a protective mechanism against drug-induced cardiotoxicity.

Antioxidants neutralize free oxygen radicals and are commonly found in dietary supplements. However, according to new research, antioxidants like vitamin C and E induce the formation of new blood vessels by activating a protein called BACH1.

Overexpression of Lysine-specific histone demethylase 1A can drive the development of cancer. Scientists have now shown that degrading the entire protein leads to better results than short-circuiting the chemical reaction leading to overexpression.

Researchers have developed a protein “envelope” that surrounds the cancer drug doxorubicin, both increasing its chances of being taken up by cancer cells and decreasing its toxic effects on lab-grown heart cells.

A study has revealed a new Australian drug demonstrates potential for treating pancreatic cancer. The drug shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer.